New global study finds: sleep apnea patients who use cpap live longer

San diego, march 19, 2025 (globe newswire) -- resmed (nyse: rmd, asx: rmd), the global leader in health technology focused on sleep, breathing, and care delivered in the home, today announced the publication of a landmark meta-analysis in the lancet respiratory medicine , demonstrating that cpap therapy significantly reduces the risk of death for people with obstructive sleep apnea (osa). analyzing data from over 1 million sleep apnea patients worldwide, the study provides the strongest evidence to date that cpap therapy not only alleviates osa symptoms but can also prolong life.
RMD Ratings Summary
RMD Quant Ranking